A matching-adjusted indirect comparison showed favorable survival outcomes with zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia.
Back
Comparing Continuous BTK Inhibitors in Treatment-Naive CLL
Talha Munir, MBChB, PhD, and colleagues conducted a matching-adjusted indirect comparison for zanubrutinib vs ibrutinib in treatment-naive CLL.
Comparing Continuous BTK Inhibitors in Treatment-Naive CLL
Episodes
All
All
Talha Munir, MBChB, PhD, discusses the implications of an MAIC comparing zanubrutinib and ibrutinib in treatment-naive CLL.
Advertisement
Advertisement
Trending on OncLive
1
Triplet Immunotherapy Regimen Yields Durable Responses in pMMR CRPC
2
FDA-Approved ADCs Prompt the Need for Revisions to the Breast Cancer Management Roadmap
3
Docirbrutinib Yields High Response Rates in MCL and CLL
4
Talk of Cure, a New ADC, and a Negative Trial: Breaking Down the Biggest Gynecologic Cancer News From ASCO 2026
5